The California Institute for Regenerative Medicine awarded $42.1 million for translational research projects. These projects target brain cancers, salivary gland conditions, and a rare metabolic disease. CIRM’s Translational program supports promising stem cell and gene projects. It helps teams complete key activities needed for clinical studies or broad use. These activities can involve therapeutic candidates, … Continue reading CIRM invests more than $42 million in translational research
Month: October 2023
CIRM-Funded Program For Rare Pediatric Disease
The California Institute for Regenerative Medicine (CIRM) congratulates Rocket Pharmaceuticals, Inc., a leading late‑stage biotechnology company. The company recently received U.S. FDA acceptance of the Biologics License Application (BLA) and Priority Review for RP-L201 (marnetegragene autotemcel). CIRM helped support development of this lentiviral‑vector gene therapy for severe Leukocyte Adhesion Deficiency‑I (LAD‑I). What the BLA Means … Continue reading CIRM-Funded Program For Rare Pediatric Disease
CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC Irvine
The California Institute for Regenerative Medicine (CIRM) Alpha Clinics network specializes in delivering stem and gene cell clinical trials to patients. The key to the network’s success is the ability to foster partnerships with patients, medical providers, and clinical trial sponsors. The CIRM Alpha Clinics Network consists of nine leading medical centers throughout California. Every … Continue reading CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC Irvine
CIRM approves new plan to invest $110 million for neuropsychiatric disease research
The California Institute for Regenerative Medicine (CIRM) approved a new program called ReMIND at its September ICOC meeting. The program will award up to $110 million to advance basic research in neuropsychiatric diseases—one of California’s largest investments in this area. ReMIND (Research using Multidisciplinary, Innovative Approaches in Neuro Diseases) aims to accelerate discoveries that improve … Continue reading CIRM approves new plan to invest $110 million for neuropsychiatric disease research